Parallax Volatility Advisers’s BioCryst Pharmaceuticals BCRX Stock Holding History

Parallax Volatility Advisers’s Portfolio BCRX Stock Details BCRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q2	–	Sell	-10,700	Closed	-$87K	–	2563
2019 Q1	$87K	Hold	10,700	–	–	﹤0.01%	2150
2018 Q4	$86K	Buy	10,700 +10,652	+22,192%	+$82.8K	﹤0.01%	1974
2018 Q3	$0	Buy	+48	New	+$322	﹤0.01%	2579
2018 Q1	–	Sell	-14,994	Closed	-$74K	–	2293
2017 Q4	$74K	Buy	+14,994	New	+$72.6K	﹤0.01%	2974

Other funds holding BCRX

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

VMI

VHCP Management II New York $379M AUM 421.62% 1-Year Est. Return

Parallax Volatility Advisers's BCRX Position: Q2 2019 in Review

Parallax Volatility Advisers sold out of BioCryst Pharmaceuticals (BCRX) in Q2 2019, closing a stake of 10,700 shares — an estimated $87K sold.

Parallax Volatility Advisers first reported a position in BCRX in Q4 2017 and held it in 4 quarters. The position peaked at $87K in Q1 2019. 116 funds tracked by Wall St. Rank hold BCRX as of Q2 2019.

Parallax Volatility Advisers reported no remaining BioCryst Pharmaceuticals position as of Q2 2019 after selling out during the quarter.
Parallax Volatility Advisers sold 10,700 BioCryst Pharmaceuticals shares in Q2 2019, an estimated $87K.
Parallax Volatility Advisers first reported a position in BioCryst Pharmaceuticals in Q4 2017 and held it in 4 quarters.
Parallax Volatility Advisers's BioCryst Pharmaceuticals position peaked at $87K in Q1 2019.
116 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q2 2019.

Based on Parallax Volatility Advisers's 13F filing for Q2 2019, filed 14 Aug 2019.